Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

488 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial.
Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y. Clauw DJ, et al. Clin Ther. 2008 Nov;30(11):1988-2004. doi: 10.1016/j.clinthera.2008.11.009. Clin Ther. 2008. PMID: 19108787 Clinical Trial.
Compared with placebo, significantly greater proportions of milnacipran-treated patients were FM composite responders (100 mg/d: P = 0.01; 200 mg/d: P = 0.02) and FM pain composite responders (100 mg/d: P = 0.03; 200 mg/d: P = 0.004). Milnacipran was a …
Compared with placebo, significantly greater proportions of milnacipran-treated patients were FM composite responders (100 mg/d: P = …
Assessment of physical function and participation in chronic pain clinical trials: IMMPACT/OMERACT recommendations.
Taylor AM, Phillips K, Patel KV, Turk DC, Dworkin RH, Beaton D, Clauw DJ, Gignac MA, Markman JD, Williams DA, Bujanover S, Burke LB, Carr DB, Choy EH, Conaghan PG, Cowan P, Farrar JT, Freeman R, Gewandter J, Gilron I, Goli V, Gover TD, Haddox JD, Kerns RD, Kopecky EA, Lee DA, Malamut R, Mease P, Rappaport BA, Simon LS, Singh JA, Smith SM, Strand V, Tugwell P, Vanhove GF, Veasley C, Walco GA, Wasan AD, Witter J. Taylor AM, et al. Pain. 2016 Sep;157(9):1836-50. doi: 10.1097/j.pain.0000000000000577. Pain. 2016. PMID: 27058676 Review.
Variations in the management of fibromyalgia by physician specialty: rheumatology versus primary care.
Able SL, Robinson RL, Kroenke K, Mease P, Williams DA, Chen Y, Wohlreich M, McCarberg BH. Able SL, et al. Pragmat Obs Res. 2016 May 20;7:11-20. doi: 10.2147/POR.S79441. eCollection 2016. Pragmat Obs Res. 2016. PMID: 27799842 Free PMC article.
The rheumatologists expressed higher confidence diagnosing FM (4.5 on a five-point scale) than primary care physicians (4.1) (P=0.037). ...
The rheumatologists expressed higher confidence diagnosing FM (4.5 on a five-point scale) than primary care physicians (4.1) (P=0.037 …
Longitudinal observation of treatment patterns and outcomes for patients with fibromyalgia: 12-month findings from the reflections study.
Robinson RL, Kroenke K, Williams DA, Mease P, Chen Y, Faries D, Peng X, Hann D, Wohlreich M, McCarberg B. Robinson RL, et al. Pain Med. 2013 Sep;14(9):1400-15. doi: 10.1111/pme.12168. Epub 2013 Jun 11. Pain Med. 2013. PMID: 23758985 Clinical Trial.
Long-term evaluation of opioid treatment in fibromyalgia.
Peng X, Robinson RL, Mease P, Kroenke K, Williams DA, Chen Y, Faries D, Wohlreich M, McCarberg B, Hann D. Peng X, et al. Clin J Pain. 2015 Jan;31(1):7-13. doi: 10.1097/AJP.0000000000000079. Clin J Pain. 2015. PMID: 24480913
RESULTS: Compared with the opioid cohort, the nonopioid cohort demonstrated significantly greater reductions (P<0.05) in BPI-I, FIQ, PHQ-8, SDS, and ISI; the tramadol cohort compared with the opioid group showed greater reductions on FIQ and ISI. ...
RESULTS: Compared with the opioid cohort, the nonopioid cohort demonstrated significantly greater reductions (P<0.05) in BPI-I, FI …
Evaluation of patient-rated stiffness associated with fibromyalgia: a post-hoc analysis of 4 pooled, randomized clinical trials of duloxetine.
Bennett R, Russell IJ, Choy E, Spaeth M, Mease P, Kajdasz D, Walker D, Wang F, Chappell A. Bennett R, et al. Clin Ther. 2012 Apr;34(4):824-37. doi: 10.1016/j.clinthera.2012.02.013. Epub 2012 Mar 14. Clin Ther. 2012. PMID: 22421576

Duloxetine significantly improved the FIQ stiffness score compared with placebo (P < 0.001) and provided a moderate effect size (0.23 for the 60-mg dose and 0.38 for the 120-mg dose). Changes in stiffness were best correlated (range, 0.52-0.75; all, P < 0.001)

Duloxetine significantly improved the FIQ stiffness score compared with placebo (P < 0.001) and provided a moderate effect size (0

The effect of duloxetine treatment on cognition in patients with fibromyalgia.
Mohs R, Mease P, Arnold LM, Wang F, Ahl J, Gaynor PJ, Wohlreich MM. Mohs R, et al. Psychosom Med. 2012 Jul-Aug;74(6):628-34. doi: 10.1097/PSY.0b013e31825b9855. Epub 2012 Jun 28. Psychosom Med. 2012. PMID: 22753629 Clinical Trial.
Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study.
Goldenberg DL, Clauw DJ, Palmer RH, Mease P, Chen W, Gendreau RM. Goldenberg DL, et al. Pain Med. 2010 Feb;11(2):180-94. doi: 10.1111/j.1526-4637.2009.00755.x. Epub 2009 Dec 9. Pain Med. 2010. PMID: 20002596 Clinical Trial.
Effects of milnacipran on the multidimensional aspects of fatigue and the relationship of fatigue to pain and function: pooled analysis of 3 fibromyalgia trials.
Mease PJ, Palmer RH, Wang Y. Mease PJ, et al. J Clin Rheumatol. 2014 Jun;20(4):195-202. doi: 10.1097/RHU.0000000000000103. J Clin Rheumatol. 2014. PMID: 24847745 Clinical Trial.

After 3 months of stable-dose treatment, patients receiving milnacipran 100 and/or 200 mg/d had significant improvement in MFI total and subscale scores (P < 0.05 vs placebo). ...Significantly more patients met the threshold of 30% or greater with milnacipran (100 mg/d,

After 3 months of stable-dose treatment, patients receiving milnacipran 100 and/or 200 mg/d had significant improvement in MFI total and sub …
488 results
Jump to page
Feedback